21:46 , Dec 1, 2017 |  BC Week In Review  |  Clinical News

JnJ begins Phase IIb trial for mosaic HIV vaccine

Johnson & Johnson (NYSE:JNJ) said it began the first trial designed to test the efficacy of a mosaic-based vaccine to prevent HIV infection. The Phase IIb trial -- Imbokodo -- is co-funded by the Bill...
00:20 , Dec 1, 2017 |  BC Extra  |  Clinical News

J&J begins Phase IIb trial of mosaic HIV vaccine

Johnson & Johnson (NYSE:JNJ) said it began the first trial designed to test the efficacy of a mosaic-based vaccine to prevent HIV infection. The Phase IIb trial -- Imbokodo -- is co-funded by the Bill...
21:03 , Jul 28, 2017 |  BC Week In Review  |  Clinical News

J&J reports first-in-human data for mosaic vaccine to prevent HIV infection

The Janssen Vaccines & Prevention B.V. unit of Johnson & Johnson (NYSE:JNJ) reported data from the Phase I/IIa APPROACH trial in 393 HIV-uninfected healthy volunteers showing that various mosaic-based prime-boost vaccine regimens utilizing the mosaic...
01:06 , Jul 25, 2017 |  BC Extra  |  Clinical News

J&J reports first-in-human data for mosaic vaccine

Johnson & Johnson (NYSE:JNJ) reported first-in-human data from the Phase Ib/IIa APPROACH study of several mosaic-based, prime-boost vaccine regimens to prevent HIV-1 infection. The company said the vaccine regimen appeared to be well-tolerated and elicited...
07:00 , Aug 8, 2016 |  BC Week In Review  |  Clinical News

Ad26: Phase I/IIa started

Johnson & Johnson’s Janssen Vaccines & Prevention B.V. unit began a double-blind, placebo-controlled, international Phase I/IIa trial to compare intramuscular doses of Ad26.Mos4.HIV vs. Ad26.Mos.HIV at weeks 0 and 12 plus booster doses of either...
07:00 , Aug 8, 2016 |  BC Week In Review  |  Clinical News

Ad26: Completed Phase I/IIa enrollment

Johnson & Johnson’s Janssen Vaccines & Prevention B.V. unit completed enrollment of about 400 healthy volunteers in a double-blind, placebo-controlled, international Phase I/IIa trial evaluating intramuscular Ad26.Mos.HIV at weeks 0 and 12 plus booster regimens...